

1

Supplementary Table 1. Trial centers and principal investigators.

Country	National coordinating center	Principal investigator
Finland	Kuopio University Hospital, Kuopio (Sponsor)	Juha Hartikainen, M.D., Ph.D.
Denmark	Region Hovestaden Rigshospitalet, Copenhagen	Jens Kastrup, M.D., Ph.D.
United Kingdom	Queen Mary University of London, London	Anthony Mathur M.B. B.Chir., Ph.D.
Austria	Medical University of Vienna, Vienna	Mariann Pavone-Gyöngyösi, M.D., Ph.D.
Spain	General University Hospital Gregorio Marañón, Madrid	Francisco Fernández-Avilés, M.D., Ph.D.
Poland	Medical University of Silesia, Katowice	Wojtek Wojakowski, M.D., Ph.D.
Poland	University of Medical Sciences, Poznań	Adrian Gwizdała, M.D., Ph.D.

Supplementary Table 2. Trial assessments and recorded data.

EVENT	Screening visit	Admission	Gene transfer	4 hours after gene transfer	Cardiac ward	Visit day 14	Visit day 180	Visit day 360	Visits years 2 and 5 §
TIME		day -1	day 0	day 0	day 1	day 14 +/- 2 days	day 180 +/- 30 days	day 360 +/- 30 days	year 2/5 +/- 1 month
1. Date of visit	X	X	X		X	X	X	X	X
2. CV history	X								
3. CV risk factors	X								
4. CV medication	X	X			X		X	X	X
5. Other medical history *	X								
6. Concomitant medication	X	X		X	X	X	X	X	X
7. Previous coronary angiography results †	X								
8. Smoking history	X								
9. Demographic data	X								
10. Working ability	X						X	X	X
11. Ophthalmologic examination ‡	X								
12. Chest X-ray	X								
13. CCS class	X						X	X	X
14. 6MWT	X						X	X	
15. PET/SPECT	X						X		
14. QoL questionnaires	X						X	X	X
15. Physical examination	X						X	X	
16. Vital signs	X			X	X		X	X	
17. Laboratory tests	X	X		X	X	X	X	X	
18. ECG	X			X	X	X	X	X	
19. TTE	X				X		X	X	
20. Symptoms	X	X	X	X	X	X	X	X	X
21. Adverse events		X	X	X	X	X	X	X	X
22. Protocol deviations	X	X	X	X	X	X	X	X	X

* Including concomitant diseases. † Within the past 12 months. ‡ For patients with diabetes. § Telephone interviews. Abbreviations: 6MWT, 6-minute walking test; CCS, Canadian Cardiovascular Society; CV, cardiovascular; ECG, electrocardiogram; PET, positron emission tomography; SPECT, single-photon emission computed tomography; TTE, transthoracic echocardiography; QoL, quality of life.

Supplementary Table 3. Planned laboratory assessments.

Time point	Laboratory assessments
Screening visit	<p>Local:</p> <ul style="list-style-type: none"> - Blood count and platelets - Plasma CRP - Plasma creatinine & estimated creatinine clearance - Plasma urea - Plasma ALT - Plasma ALP - Plasma bilirubin - Plasma fasted blood glucose - Blood HbA1c - Plasma sodium - Plasma potassium - Plasma CK - Plasma CK-MBm - Plasma TnT - Plasma PSA (men) - Plasma proBNP - Plasma fasted total cholesterol, HDL, LDL, triglycerides - Plasma hCG (women) - Urine analysis (urine test strip) <p>AIVI:</p> <ul style="list-style-type: none"> - Lp(a) - OxLDL - Anti-adenovirus antibody 1 - Anti-VEGF-D antibody 1 - VEGF-D ELISA - Serum and urine adenovirus DNA qPCR
Before gene transfer	<p>Local:</p> <ul style="list-style-type: none"> - Blood count and platelets - Plasma CRP - Plasma creatinine - Plasma sodium - Plasma potassium - Plasma CK - Plasma CK-MBm - Plasma TnT - Plasma proBNP - Plasma INR if necessary *

4

Four hours after the gene transfer	<ul style="list-style-type: none"> - Blood count and platelets - Plasma CRP - Plasma creatinine - Plasma CK - Plasma CK-MBm - Plasma TnT - Plasma INR if necessary * <p>AIVI:</p> <ul style="list-style-type: none"> - VEGF-D ELISA - Serum and urine adenovirus DNA qPCR
One day after the gene transfer	<p>Local:</p> <ul style="list-style-type: none"> - Blood count and platelets - Plasma CRP - Plasma sodium - Plasma potassium - Plasma CK - Plasma CK-MBm - Plasma TnT - Plasma proBNP - Plasma INR if necessary *
Two days after the gene transfer or just prior to the patient's discharge	<p>Local:</p> <ul style="list-style-type: none"> - Blood count and platelets - Plasma CRP - Plasma creatinine & estimated creatinine clearance - Plasma urea - Plasma sodium - Plasma potassium - Plasma ALT - Plasma ALP - Plasma bilirubin - Plasma fasted blood glucose - Blood HbA1c - Plasma CK - Plasma CK-MBm - Plasma TnT - Plasma proBNP <p>AIVI:</p> <ul style="list-style-type: none"> - VEGF-D ELISA - Serum and urine adenovirus DNA qPCR
14 days after the gene transfer	<p>Local:</p> <ul style="list-style-type: none"> - Blood count and platelets

	<ul style="list-style-type: none"> - Plasma CRP - Plasma creatinine & estimated creatinine clearance - Plasma urea - Plasma sodium - Plasma potassium - Plasma ALT - Plasma ALP - Plasma bilirubin - Plasma fasted blood glucose - Blood HbA1c - Plasma CK - Plasma CK-MBm - Plasma TnT - Plasma proBNP <p>AIVI:</p> <ul style="list-style-type: none"> - Anti-adenovirus antibody 2 - Anti-VEGF-D antibody 2 - VEGF-D ELISA - Serum and urine adenovirus DNA qPCR
180 days after the gene transfer	<p>Local:</p> <ul style="list-style-type: none"> - Blood count and platelets - Plasma CRP - Plasma creatinine & estimated creatinine clearance - Plasma urea - Plasma ALT - Plasma ALP - Plasma bilirubin - Plasma fasted blood glucose - Blood HbA1c - Plasma sodium - Plasma potassium - Plasma CK - Plasma CK-MBm - Plasma TnT - Plasma PSA (men) - Plasma proBNP - Plasma fasted total cholesterol, HDL, LDL, triglycerides - Plasma hCG (women) - Urine analysis (urine test strip) <p>AIVI:</p>

6

	<ul style="list-style-type: none"> - Anti-adenovirus antibody 3 - Anti-VEGF-D antibody 3 - VEGF-D ELISA - Serum and urine adenovirus DNA qPCR
360 days after the gene transfer	<p>Local:</p> <ul style="list-style-type: none"> - Blood count and platelets - Plasma CRP - Plasma creatinine & estimated creatinine clearance - Plasma urea - Plasma ALT - Plasma ALP - Plasma bilirubin - Plasma fasted blood glucose - Blood HbA1c - Plasma sodium - Plasma potassium - Plasma CK - Plasma CK-MBm - Plasma TnT - Plasma PSA (men) - Plasma proBNP - Plasma fasted total cholesterol, HDL, LDL, triglycerides - Plasma hCG (women) - Urine analysis (urine test strip) <p>AIVI:</p> <ul style="list-style-type: none"> - Anti-adenovirus antibody 4 - Anti-VEGF-D antibody 4 - VEGF-D ELISA - Serum and urine adenovirus DNA qPCR

* For patients using a vitamin K antagonist. AIVI, A.I. Virtanen Institute for Molecular Sciences; ALP, alkaline phosphatase; ALT, alanine aminotransferase; CK, creatine kinase; CRP, C-reactive protein; DNA, deoxyribonucleic acid; ELISA, enzyme-linked immunosorbent assay; HbA1c, glycated hemoglobin; hCG, human chorionic gonadotropin; HDL, high-density lipoprotein; INR, international normalized ratio; LDL, low-density lipoprotein; Lp(a), lipoprotein(a); OxLDL, oxidized low-density lipoprotein; proBNP, pro brain natriuretic peptide; PSA, prostate-specific

7

antigen; qPCR, quantitative polymerase chain reaction; TnT, troponin T; VEGF-D, vascular endothelial growth factor-D.